FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
01.12.2022 - Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) - Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of ... Seite 1
Nuvectis Pharma Inc About Fast Track Fast Track Designation Accelerated Approval Priority Review Nuvectis Pharma
Source: wallstreet-online.de